Abstract
The oral administration of bromocriptine induces a variety of side-effects in about 50–70% of patients, the most common being nausea and vomiting, probably related to the local gastrointestinal effect of the drug. Nasal administration makes it possible to avoid intestinal and liver metabolism. This study compared the serum concentrations of bromocriptine and prolactin (PRL) in twenty puerperal women who had asked to discontinue breast feeding and were randomized to receive a single oral (2.5 mg) or nasal spray dose (0.8 mg) of bromocriptine. Serum bromocriptine and PRL concentrations were measured at various times before and after drug administration. At 15 min, the circulating concentrations of bromocriptine were about eight times higher after nasal than after oral administration; peak serum concentration (CMax) was reached respectively 45 min and 60 min after administration, and was about three times higher after nasal administration (314±102 pg/ml vs 112.30±34.47 pg/ml). The reduction in serum PRL concentrations was also more rapid in the nasally-treated group reaching the normal assay range of < 20 µg/l within two as against five hours post-administration. Four orally-treated patients complained of nausea; in the nasally-treated group, six patients reported only a mild endonasal burning that disappeared within a few minutes of administration. Our results suggest that the nasal administration of bromocriptine may lead to a reduction in the required overall dose and fewer gastrointestinal side-effects, and may therefore improve therapy compliance.
Similar content being viewed by others
References
Cuellar F.G. Bromocriptine mesylate (Parlodel) in the management of amenorrhea-galactorrhea associated with hyperprolactinemia. Obstet. Gynecol. 55: 278, 1980.
Friesen H., Tolis G. Use of bromocriptine in the galactorrhea-amenorrhea syndromes. The Canadian Cooperative Study. Clin. Endocrinol. (Oxf.) 6 (suppl): 915, 1977.
Metha A.E., Tolis G. Pharmacology of bromocriptine in health and disease. Drugs 77: 313, 1979.
Schran H.F., Bhuta S.I., Schwarz H.J., Thorner M.O. The pharmacokinetics of bromocriptine in man. In: Goldstein M., Calne D., Leiberman A., Thorner M.O. (Eds), Ergot compounds and brain function: Neuroendocrine and neuropsychiatric aspects. Raven Press, New York, 1980, p. 125.
Montini M., Pagani G., Gianola D., Pagani M.D., Salmoiraghi M., Ferrari L, Lancranjan I. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine. J. Clin. Endocrinol. Metab. 63: 266, 1986.
Rolland R. On ParlodeIR LAR and optimal treatment of hyperprolactinemia. In: Pepperel R.J. (Ed), New Aspects of dopamine agonist therapy in menstrual cycle disorders and infertility. The Parthenon Publishing Group, Casterton Hall, Carnforth, Lancs UK, 1990, p. 33.
Vermesh M., Fossum G.T., Kletzky O.A. Vaginal bromocriptine: Pharmacology and effect on serum prolactin in normal women. Obstet. Gynecol. 72: 693, 1988.
Katz E., Weiss B.E., Hassell A., Schran H.F., Adashi E.Y. Increased circulating levels of bromocriptine after vaginal compared with oral administration. Fertil. Steril. 55: 882, 1991.
Sarkar M.A. Drug metabolism in the nasal mucosa. Pharm. Res. 9: 1, 1992.
Cicinelli E., Ragno G., Cagnazzo I., Fanelli F., Vetuschi C., Schonauer S. Progesterone administration by nasal spray. Fertil. Steril. 56: 139, 1991.
Gopinath P.G., Gopinath R.D., Anad Kumar T.C. Target site of intranasally sprayed substances and their transport across the nasal mucosa: a new insight into intranasal route of drug delivery. Curr. Ther. Res. 23: 596, 1978.
Aeilig W.H., Nuesch E. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Int. J. Clin. Pharmacol. Res. 15: 106, 1977.
Rosenthaler J., Munzer H., Voges R. Immunoassay of bromocriptine and specificity of antibody: Criteria for choice of antiserum and marker compound. In: Reid E., Leppard J.P. (Eds), Drug metabolite isolation and determination. Plenum Press, New York and London, 1983, p. 215.
Jagannadha R.A., Moudal N.R., Li C.H. Beta-Endorphin: intranasal administration increases the serum prolactin level in monkeys. Int. J. Pept. Protein Res. 28: 546, 1986.
Faraj J.A., Hussain A.A., Aramaki Y., Iseki K., Kagoshima M., Dittert L.W. Mechanism of nasal absorption of drugs. Ill: Nasal absorption of leucine enkephalin. J. Pharm. Sci. 79: 698, 1990.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cicinelli, E., Cignarelli, M., Petruzzi, D. et al. Nasal spray vs oral administration of bromocriptine: Pharmacology and effect on serum prolactin in puerperal women. J Endocrinol Invest 19, 427–432 (1996). https://doi.org/10.1007/BF03349887
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349887